PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsRemdesivir
Veklury(remdesivir)
Veklury (remdesivir) is a small molecule pharmaceutical. Remdesivir was first approved as Veklury on 2020-07-03. It is used to treat coronavirus infections and virus diseases in the USA. It is known to target ORF1a polyprotein;ORF1ab polyprotein.
Download report
Favorite
COVID-19
FDA Novel Drug Approvals 2020
Case Study: COVID-19
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
Trade Name
FDA
EMA
Veklury (discontinued: Veklury)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Remdesivir
Tradename
Company
Number
Date
Products
VEKLURYGilead SciencesN-214787 RX2020-10-22
1 products, RLD, RS
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
vekluryNew Drug Application2025-10-13
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
coronavirus infectionsEFO_0007224D018352B34.2
virus diseases—D014777B34
Agency Specific
FDA
EMA
Expiration
Code
REMDESIVIR, VEKLURY, GILEAD SCIENCES INC
2025-10-22NCE
2025-04-25NPP
2025-01-21D-183
Patent Expiration
Patent
Expires
Flag
FDA Information
Remdesivir, Veklury, Gilead Sciences Inc
114911692041-05-28U-3484, U-3485
106752962038-07-10DP
112666812038-07-10U-2984, U-3249, U-3367, U-3368
106953612036-09-16U-2984, U-3249, U-3367, U-3368
110072082036-09-16U-2984, U-3249, U-3367, U-3368
113829262036-09-16U-3367, U-3368
97243602035-10-29DS, DP
99499942035-10-29DP
114923532031-12-08DP
100659582031-09-16DP
80082642029-09-06DS, DP
RE467622029-04-22DS, DP
83186822029-04-22DS, DP
ATC Codes
J: Antiinfectives for systemic use
— J05: Antivirals for systemic use
— J05A: Direct acting antivirals
— J05AB: Nucleosides and nucleotides excl. reverse transcriptase inhibitors
— J05AB16: Remdesivir
HCPCS
No data
Clinical
Clinical Trials
129 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Covid-19D000086382—U07.1138—414
Coronavirus infectionsD018352EFO_0007224B34.2——2——2
Severe acute respiratory syndromeD045169EFO_0000694J12.81——2——2
Virus diseasesD014777—B34——2——2
Coronaviridae infectionsD003333EFO_0007223———2——2
Nidovirales infectionsD030341EFO_0007396———2——2
Rna virus infectionsD012327————2——2
PneumoniaD011014EFO_0003106J18——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Ebola hemorrhagic feverD019142EFO_0007243A98.4—1———1
Multiple myelomaD009101—C90.0—1———1
LymphomaD008223—C85.9—1———1
Respiratory syncytial virus infectionsD018357EFO_1001413——1———1
Kidney transplantationD016030———1———1
Indications Phases 1
No data
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
InfectionsD007239EFO_0000544—————11
Communicable diseasesD003141——————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameRemdesivir
INN—
Description
Remdesivir is a carboxylic ester resulting from the formal condensation of the carboxy group of N-[(S)-{[(2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl]methoxy}(phenoxy)phosphoryl]-L-alanine with the hydroxy group of 2-ethylbutan-1-ol. A broad-spectrum antiviral prodrug with potent in vitro antiviral activity against a diverse panel of RNA viruses such as Ebola virus, MERS-CoV and SARS-CoV. It is currently in Phase III clinical trials for the treatment of Covid-19 in adults. It has a role as an antiviral drug, a prodrug and an anticoronaviral agent. It is a carboxylic ester, a pyrrolotriazine, a nitrile, a phosphoramidate ester, a C-nucleoside and an aromatic amine. It is functionally related to a GS-441524.
Classification
Small molecule
Drug classantivirals: adenosine analogs acting as RNA polymerase inhibitors
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CCC(CC)COC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@](C#N)(c2ccc3c(N)ncnn23)[C@H](O)[C@@H]1O)Oc1ccccc1
Identifiers
PDB—
CAS-ID1809249-37-3
RxCUI—
ChEMBL IDCHEMBL4065616
ChEBI ID—
PubChem CID121304016
DrugBankDB14761
UNII ID—
Target
Agency Approved
No data
Alternate
ORF1ab
ORF1ab
Organism
SARS coronavirus Tor2
Gene name
ORF1ab
Gene synonyms
NCBI Gene ID
1489680
Protein name
ORF1a polyprotein;ORF1ab polyprotein
Protein synonyms
ORF1ab polyprotein, polyprotein pp1a, polyprotein pp1ab, replicase 1AB
Uniprot ID
P59641
Mouse ortholog
—
—
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Veklury – Gilead Sciences
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 32,409 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
10,617 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use